Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|4|229-248

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.4, 2005-06, pp. : 229-248

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting vascular endothelial growth factor in angina therapy

By Boodhwani Munir   Ramlawi Basel   Laham Roger J   Sellke Frank W  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 1, 2006-02 ,pp. : 5-14

Informa Healthcare

Access to resources Recommend Favorite

Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

By  

Current Drug Targets, Vol. 11, Iss. 8, 2010-01 ,pp. : 1000-1017

Bentham Science Publishers

Access to resources Recommend Favorite

Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development

By Sepp-Lorenzino Laura   Thomas Kenneth A  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 10, 2002-10 ,pp. : 1447-1465

Informa Healthcare

Access to resources Recommend Favorite

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Anti-leukemic Therapy as Disease-stabilizing Treatment for Acute Myeloid Leukemia Relapse after Allogeneic Stem Cell Transplantation: Will it be Possible to Combine these Strategies with Retransplantation or Donor Lymphocyte Infusions?

By  

Current Cancer Drug Targets, Vol. 13, Iss. 1, 2013-01 ,pp. : 30-47

Bentham Science Publishers

Access to resources Recommend Favorite